These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 3051488)

  • 1. [Interleukin 2].
    Voĭtenok NN
    Ter Arkh; 1988; 60(5):42-6. PubMed ID: 3051488
    [No Abstract]   [Full Text] [Related]  

  • 2. [Interleukin-2 and cancer immunotherapy].
    Ogarkov VI; Dobkin AI; Ryzhova EV; Okulov VB; Kiselev OI
    Vopr Onkol; 1989; 35(2):141-50. PubMed ID: 2648678
    [No Abstract]   [Full Text] [Related]  

  • 3. Natural killer cells and tumor immunity: 1985.
    Herberman RB
    Year Immunol; 1986; 2():254-60. PubMed ID: 3033946
    [No Abstract]   [Full Text] [Related]  

  • 4. The role of rIL-2 in the modulation of cellular immunity in resistance to infection.
    Kaplan G
    Behring Inst Mitt; 1991 Feb; (88):228-9. PubMed ID: 2049043
    [No Abstract]   [Full Text] [Related]  

  • 5. Interleukins and the immune system 1.
    O'Garra A
    Lancet; 1989 Apr; 1(8644):943-7. PubMed ID: 2565429
    [No Abstract]   [Full Text] [Related]  

  • 6. The preclinical screening laboratory: evaluation of immunomodulatory and therapeutic properties of biological response modifiers.
    Talmadge JE; Herberman RB
    Cancer Treat Rep; 1986 Jan; 70(1):171-82. PubMed ID: 3510733
    [No Abstract]   [Full Text] [Related]  

  • 7. Interleukin-2 and cancer--physiological and pharmacological uses.
    Huland E
    Folia Biol (Praha); 2001; 47(4):111-2. PubMed ID: 11508853
    [No Abstract]   [Full Text] [Related]  

  • 8. Inhibition by selected anticancer agents of the development of primary cell-mediated immunity against allogeneic tumor cells in culture.
    Orsini F; Eppolito C; Ehrke MJ; Mihich E
    Cancer Treat Rep; 1980; 64(2-3):211-8. PubMed ID: 6967756
    [No Abstract]   [Full Text] [Related]  

  • 9. Rationale and therapeutic basis for patients receiving recombinant interleukin-2.
    Dudjak LA
    Semin Oncol Nurs; 1993 Aug; 9(3 Suppl 1):3-7. PubMed ID: 8210792
    [No Abstract]   [Full Text] [Related]  

  • 10. Complete regression of experimental solid tumors by combination LEC/chTNT-3 immunotherapy and CD25(+) T-cell depletion.
    Li J; Hu P; Khawli LA; Epstein AL
    Cancer Res; 2003 Dec; 63(23):8384-92. PubMed ID: 14679000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human and mouse "LAK" cells expanded in long-term cultures: in vitro and in vivo studies.
    Kedar E; Zeira E; Lebendiker Z; Weiss DW; Katan R; Shouval D
    Prog Clin Biol Res; 1987; 244():59-75. PubMed ID: 3498959
    [No Abstract]   [Full Text] [Related]  

  • 12. [Human interleukin 2].
    Chouaib S; Fradelizi D
    Ann Immunol (Paris); 1983; 134D(2):157-65. PubMed ID: 6419669
    [No Abstract]   [Full Text] [Related]  

  • 13. Chemically engineered bispecific antibody directed at the p55 and p75 chains of the human interleukin 2 receptor: specific high-affinity cross-linking of p55/p75 complexes and high blocking effect on IL2-induced T cell proliferation.
    François C; Boeffard F; Jacques Y
    Transplant Proc; 1993 Feb; 25(1 Pt 1):815-6. PubMed ID: 8438495
    [No Abstract]   [Full Text] [Related]  

  • 14. Interleukin-2: its rationale and role in the treatment of patients with cancer.
    Rubin JT
    Cancer Treat Res; 1995; 80():83-105. PubMed ID: 8821575
    [No Abstract]   [Full Text] [Related]  

  • 15. Human interleukin-2-IgM heavy-chain-fusion proteins are cytotoxic for cells expressing the IL2 receptor.
    Vie H; Gauthier T; Breathnach R; Bonneville M; Godard A; Dietrich J; Karam G; Gesnel MC; Peyrat MA; Jacques Y
    Transplant Proc; 1993 Feb; 25(1 Pt 1):741-2. PubMed ID: 8438463
    [No Abstract]   [Full Text] [Related]  

  • 16. In vivo and in vitro activation of NK cytotoxicity with IL-2.
    Ibayashi Y; Tokuda Y; Saks ER; Sarna GP; Golub SH
    Prog Clin Biol Res; 1987; 244():275-85. PubMed ID: 3498954
    [No Abstract]   [Full Text] [Related]  

  • 17. Interleukin-2 and the interleukin-2 receptor complex.
    Gaulton GN; Williamson P
    Chem Immunol; 1994; 59():91-114. PubMed ID: 7945931
    [No Abstract]   [Full Text] [Related]  

  • 18. Natural killer cells and their possible relevance to transplantation biology.
    Herberman RB
    Transplantation; 1982 Jul; 34(1):1-7. PubMed ID: 6214877
    [No Abstract]   [Full Text] [Related]  

  • 19. Phase I trial of recombinant interleukin-2 and cyclophosphamide: augmentation of cellular immunity and T-cell mitogenic response with long-term administration of rIL-2.
    Kolitz JE; Wong GY; Welte K; Merluzzi VJ; Engert A; Bialas T; Polivka A; Bradley EC; Konrad M; Gnecco C
    J Biol Response Mod; 1988 Oct; 7(5):457-72. PubMed ID: 3263471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Regulation of the immune response mediated by cellular interactions. Its relation to anti-tumor immunity].
    Hajos SE
    Rev Argent Microbiol; 1987; 19(2):81-90. PubMed ID: 3332380
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.